Roche: Patent ruling won't stop Mircera

Roche has lost turf to Amgen in their patent battle over Mircera, an anti-anemia drug now under FDA review. A federal judge says that yes, the Roche remedy does infringe on an Amgen patent. Amgen's other patent claims against Mircera are scheduled to go to trial next week.

Amgen, of course, sells the blockbuster anti-anemia drugs Aranesp and Epogen--and they're both crucial to the company's health. In after-hours trading, Amgen was up 1.8 percent on the news; Roche stock had lost 1.8 percent. For its part, Roche says it plans to defy the ruling and launch Mircera in the U.S. as soon as it gets FDA approval. The judge's ruling doesn't affirm the validity of Amgen's patents, the company said in a statement.

- check out this release
- here's the AP report

Related Articles:
Roche to Launch Mircera in U.K. and Germany. Report
FDA wants more data on new Aranesp doses. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.